SCHEMBL6803855

SCHEMBL6803855

O=c1c2cc(F)c(N3CCCC3)nc2n(C2CC2)c(=O)n1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 3/20 0.37
EEF2 P13639 1/20 0.37
PIK3CA P42336 4/20 0.36
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.34
CYP2C9 P11712 1/20 0.34
ATP6V1B2 P21281 1/20 0.34
TBXA2R P21731 1/20 0.34
EDNRA P25101 1/20 0.34
TARBP2 Q15633 1/20 0.34
DPP4 P27487 4/20 0.34
TOP2A P11388 1/20 0.33
TOP2B Q02880 1/20 0.33
EPHA2 P29317 1/20 0.32
FLT4 P35916 1/20 0.32
GSK3B P49841 1/20 0.32
RARB P10826 1/20 0.32
TBXAS1 P24557 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801320 0.90 ALDH1A1 (0.40) EEF2KEEF2KMT2ALMNACYP2C9
Hydrochloric Acid SCHEMBL7007854 0.89 ALDH1A1 (0.40) EEF2KEEF2KMT2ALMNACYP2C9
SCHEMBL6802354 0.84 EPHA2 (0.48) EEF2KEEF2PIK3CAKMT2ALMNA
SCHEMBL6801438 0.79 LMNA (0.43) EEF2KEEF2KMT2ALMNACYP2C9
SCHEMBL6795621 0.77 KMT2A (0.42) KMT2ALMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL6801910 0.77 L3MBTL1 (0.37) KMT2ACYP2C9DPP4
SCHEMBL6801451 0.77 LMNA (0.39) KMT2ALMNAFEN1
SCHEMBL6800863 0.77 FEN1 (0.38) KMT2ALMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL6802382 0.77 LMNA (0.42) KMT2ALMNACYP2C9TOP2ATOP2B
SCHEMBL6801398 0.75 ALDH1A1 (0.37) KMT2ALMNACYP2C9ATP6V1B2TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US claimed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A EEF2K 116/4885EEF2 248/4885PIK3CA 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.